HANOVER, Md., June 26 /PRNewswire/ -- NovaScreen Biosciences Corporation, a Caliper Life Sciences Company, today announced that Wyeth Pharmaceuticals, a division of Wyeth , has selected NovaScreen to conduct a high-throughput screening (HTS) campaign. As a result, NovaScreen will screen 500,000 compounds against an inflammatory target.
The HTS campaign combines NovaScreen’s kinase profiling expertise with Caliper’s LabChip(R) 3000 microfluidic screening platform, which utilizes electrophoretic separation of assay components to provide analytical quality data that is highly reproducible.
Performing the screen using LabChip 3000 technology assures exceptional data quality that helps eliminate false positives in the primary screen, providing more relevant and accurate information. Accessing the technology through collaboration with NovaScreen provides companies with screening data that shapes their drug discovery efforts by identifying novel compounds that may get overlooked with other techniques.
“NovaScreen provides another avenue for companies to access Caliper’s proven microfluidic technology,” said David Manyak, president of NovaScreen Biosciences. “Pharmaceutical companies can outsource screening projects to NovaScreen to ensure that the highest quality technologies are used without the upfront investment to purchase in-house systems.”
About NovaScreen Biosciences
NovaScreen Biosciences Corporation, a Caliper Life Sciences company, is a leading provider of drug discovery and development services and products, with a focus on in vitro (laboratory-based) screening assays and in silico (computer-based) predictive screening tools. Services and products are provided to more than 180 clients worldwide, including a majority of the leading drug and biotechnology companies. http://www.NovaScreen.com
Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.
NovaScreen Biosciences Corporation
CONTACT: Stacey Holifield of Schwartz Communications, +1-781-684-0770,caliper@schwartz-pr.com, for NovaScreen Biosciences; or Renee Zeppetello ofNovaScreen Biosciences, +1-410-961-9317, rzeppetello@novascreen.com
